Loading
A phase 1/2 trial of Varsetatug masetecan run by CytomX Therapeutics, not yet recruiting.
Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer is a phase 1/2 interventional study registered as NCT07900165 by CytomX Therapeutics, with 368 participants planned, started 2026-12. Conditions recorded: Colo-rectal Cancer. Interventions recorded: varsetatug masetecan, bevacizumab + 5-FU + leucovorin and bevacizumab.
Shares Varsetatug masetecan, CytomX Therapeutics and the tag pipeline.
Shares CytomX Therapeutics and the tag pipeline.
Shares CytomX Therapeutics and the tag pipeline.
Shares CytomX Therapeutics and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/